The Federal Reserve’s plan to curtail its extraordinary stimulus will inject considerable uncertainty into the market over the next six months. That’s why utility investors should be extremely conservative and invest in only the highest quality stocks and bonds until the market’s direction becomes clearer.
What kinds of securities meet our stringent criteria? We favor stocks whose underlying companies generate strong earnings that support both long-term valuations as well as dividend growth. Additionally, these utilities must also sport solid balance sheets with manageable debt burdens.
Equally important, such fundamentally superior firms should do a better job than their peers of holding their value in the event of a short-term correction. Finally, in a rising interest-rate environment these securities will need to offer competitive yields.
The current investment climate is exceedingly tricky to analyze. Some forecasters say the US economy is on the upswing and will support rising market valuations even as the stimulus recedes. Meanwhile, other market gurus worry that the Fed is acting too quickly, as the economy may not be ready to support itself without the continuing largesse of our central bank.
Best Consumer Companies To Watch For 2015: Cornerstone Strategic Value Fund Inc (CLM)
Cornerstone Strategic Value Fund, Inc. (the Fund), incorporated on May 1, 1987, is a closed-end, diversified management investment company. The Fund invests in equity securities of companies listed in the United States. Cornerstone Strategic Value Fund, Inc. invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, consumer staples, energy, utilities, telecommunication services, materials and other sectors.
As of December 31, 2005, the Fund's top 10 holdings were General Electric Co., Exxon Mobil Corp., Microsoft Corp., Citigroup Inc., Procter & Gamble Co. (The), EMC Corp., Bank of America Corp., American International Group, Inc., Johnson & Johnson and Pfizer Inc. Cornerstone Strategic Value Fund, Inc.'s investment manager is Cornerstone Advisors, Inc.
Advisors' Opinion:- [By Dividends4Life]
According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund�� market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 3.46%Bexil Advisers LLC� (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer
10 Best Quality Stocks To Own For 2014: Tetraphase Pharmaceuticals Inc (TTPH)
Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company�� product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company are developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. The Company�� frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. In 2012, in vitro experiments, eravacycline has demonstrated the ability to cover a variety of multi-drug resistant Gram-negative, Gram-positive, anaerobic and atypical bacteria, including multi-drug resistant Klebsiella pneumoniae, the species of Gram-negative bacteria that killed seven patients at the Clinical Center of the National Institutes of Health.
Gram-positive bacteria that have developed resistance to existing drugs include: Streptococcus pneumoniae that cause pneumonia, ear infections, bloodstream infections and meningitis; Staphylococcus aureus that cause skin, bone, lung and bloodstream infections, and Enterococci that are responsible for infections transmitted in healthcare settings. Gram-negative bacteria that have developed resistance to existing drugs include: Escherichia coli that cause urinary tract, skin and bloodstream infections; Salmonella and Escherichia coli that cause foodborne infections, and Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp.
In addition, other antibiotics that have been used as first-line empiric monothe! rapies, such as Levaquin, piperacillin/tazobactam, which is marketed by Pfizer as Zosyn, carbapenems, such as Merrem, and imipenem/cilastatin, which is marketed by Merck as Primaxin, have seen their utility as first-line empiric monotherapies diminished as the number of bacterial strains resistant to these therapies has increased. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. A number of previous tetracyclines have been available in both intravenous and oral dosage forms. Infections that are resistant to existing oral drugs are increasingly common, and the Company believe that an intravenous-to-oral step-down therapy in which patients are started on the intravenous formulation of eravacycline and then stepped down to an oral formulation of eravacycline could reduce the length of a patient�� hospital stay or help avoid hospital admission altogether, lowering the overall cost of care for these patients.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Tetraphase Pharmaceuticals (TTPH), which using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. This stock is off to a strong start in 2013, with shares up 19.4%.
If you take a look at the chart for Tetraphase Pharmaceuticals, you'll notice that this stock has just started to trend back above its 50-day moving average of $7.76 a share with decent upside volume flows. That move is quickly pushing shares of TTPH within range of breaking out above some key near-term overhead resistance levels that have acted as a ceiling for the stock for the last three months.
Market players should now look for long-biased trades in TTPH if it manages to break out above some near-term overhead resistance levels at $8.30 to $8.40 a share and then once it takes out more resistance at $8.50 to $9 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 62,234 shares. If that breakout triggers soon, then TTPH will set up to re-test or possibly take out its all-time high at $9.66 a share. Any high-volume move above that level will then push TTPH into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $12 to $13 a share.
Traders can look to buy TTPH off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $7.76 a share, or below more key near-term support levels at $7.37 to $7.02 a share. One can also buy TTPH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
10 Best Quality Stocks To Own For 2014: Quanex Building Products Corporation(NX)
Quanex Building Products Corporation provides engineered products and aluminum sheet products. Its Engineered Products segment produces window and door components for original equipment manufacturers that primarily serve the residential construction and remodeling markets. This segment?s products consist of insulating glass spacer/sealant systems, thin film solar panel sealants, window and patio door screens, aluminum cladding and other roll formed metal window components, thresholds and astragals, moldings, residential exterior products, engineered vinyl and composite patio doors, window profiles and custom window grilles, and trim and architectural moldings in various woods primarily for the home improvement and residential construction markets. The company?s Aluminum Sheet Products segment includes reducing reroll coil to specific gauge, annealing, slitting, and custom coating. This segment?s products are used in customer end-use applications comprising window screen fr ames and screens, exterior home trim, fascias, roof edgings, soffits, downspouts, and gutters in the building and construction markets, as well as capital goods and transportation markets. The company offers its products to original equipment manufacturers and distributors through direct and indirect sales groups primarily in the United States, Mexico, Canada, Asia, and Europe. Quanex Building Products Corporation is based in Houston, Texas.
Advisors' Opinion:- [By Seth Jayson]
When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Quanex Building Products (NYSE: NX ) .
10 Best Quality Stocks To Own For 2014: YPF Sociedad Anonima(YPF)
YPF SOCIEDAD ANONIMA, an energy company, engages in the exploration, development, and production of crude oil, natural gas, and liquefied petroleum gas (LPG) in Argentina. The company also involves in refining, marketing, transportation, and distribution of oil and a range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels; and gas separation and natural gas distribution operations. As of December 31, 2010, it had proved reserves of approximately 531 million barrels of oil and 2,533 billion cubic feet of gas; and retail distribution network of 1,622 YPF-branded service stations for automotive petroleum products. The company?s crude oil transportation network includes approximately 2,700 kilometers of crude oil pipelines with approximately 640,000 barrels of aggregate daily transportation capacity of refined products; crude oil tankage of approximately 7 million barrels; and terminal facilities at 5 Argentine ports. In addition, it participates in 3 power stations with an aggregate installed capacity of 1,622 megawatts. The company was founded in 1977 and is based in Buenos Aires, Argentina. YPF SOCIEDAD ANONIMA is a subsidiary of Repsol YPF, S.A.
Advisors' Opinion:- [By fedezaldua]
Last year, the Argentinean government nationalized 51% of YPF (YPF) from Madrid based Repsol (REPYY), which still holds a 12.4% stake in Argentina's biggest oil and gas company. When the nationalization happened, Argentina's government argued that the Spanish group had not been investing enough in the country. Hence, the lack of investments had left Argentina without its very much appreciated external surplus in oil and gas. Even when its true that YPF's Capex investments were kept at a minimum level from 2003 to 2011, its also true that low Capex was a direct result of Argentina's (very) poor and unsustainable energy policies.
10 Best Quality Stocks To Own For 2014: Carriage Services Inc (CSV)
Carriage Services, Inc. (Carriage), incorporated in December 1993, is a provider of death care services and merchandise in the United States. The Company operates in two business segments: funeral home operations and cemetery operations. As of December 31, 2011, the Company operated 159 funeral homes in 25 states and 33 cemeteries in 12 states. The Company provides funeral and cemetery services and products on both an at-need (time of death) and preneed (planned prior to death) basis. During the year ended December 31, 2011, Carriage completed two of the six acquisitions of funeral home businesses, one in Kentucky and the other in New York. In September 2011, the Company acquired Franklin & Downs Funeral Homes. In October 2011, the Company acquired Carman Funeral Home and Roberson Funeral Home, both in Northeast Kentucky. In February 2012, the Company acquired James J. Terry Funeral Home, Inc. On February 21, 2012, the Company acquired a funeral home business in Pennsylvania. In June 2012, the Company acquired Lawton Ritter Gray Funeral Home, Gray Funeral Home and Sunset Memorial Gardens in Lawton and Grandfield, Oklahoma. In December 2012, the Company acquired Cumby Family Funeral Service. In November 2013, Carriage Services Inc acquired Heritage Funeral Homes & Cremation Service.
Funeral Home Operations
The funeral homes offer a range of services (traditional burial and cremation) to meet a family�� death care needs, including consultation, the removal and preparation of remains, the sale of caskets and related funeral merchandise, the use of funeral home facilities for visitation and services, and transportation services. It provides burial and cremation services and sells related merchandise, such as caskets and urns. As of December 31, 2011, the Company operated 159 funeral homes in 25 states.
Cemetery Operations
The Company�� cemetery products and services include interment services, the rights to interment in cemetery sites (including gr! ave sites, mausoleum crypts and niches) and related cemetery merchandise, such as memorials and vaults. As of December 31, 2011, the Company operated 33 cemeteries in 12 states.
The Company competes with SCI, Stewart and StoneMor Partners L.P.
Advisors' Opinion:- [By Dan Caplinger]
The first thing to realize about StoneMor is that arcane and flexible accounting rules make it important to dig beneath its GAAP earnings. Growth throughout the industry has been substantial, as up-and-coming Carriage Services (NYSE: CSV ) continued to stay on pace for double-digit sales growth as it rapidly expands its reach. Even well-established player Matthews International (NASDAQ: MATW ) managed to grow revenue by nearly 14% in the quarter that ended in March, although its earnings fell slightly from the year-ago quarter. Still, StoneMor's sales haven't been able to rise as quickly as its peers, with its previous report including just a 6% gain in revenue.
- [By Rich Duprey]
Death services specialist�Carriage Services (NYSE: CSV ) announced today its third-quarter dividend of $0.025 per share, the same rate it's paid since 2011.
10 Best Quality Stocks To Own For 2014: The Charles Schwab Corporation(SCHW)
The Charles Schwab Corporation, through its subsidiaries, provides securities brokerage, banking, and related financial services to individuals and institutional clients. It offers various brokerage products and services comprising brokerage accounts with check-writing features, debit card, and billpay; individual retirement accounts; retirement plans for small to large businesses; college savings accounts; designated brokerage accounts; equity incentive plan accounts; and margin loans, as well as access to fixed income securities, equity and debt offerings, options, and futures. The company also provides various banking products and services, including checking accounts linked to brokerage accounts, savings accounts, certificates of deposit, demand deposit accounts, first mortgages, home equity lines of credit, and personal loans collateralized by securities. In addition, it offers trust custody services, personal trust reporting services, and administrative trustee servi ces; advisory services comprising separately managed accounts, customized personal advice for tailored portfolios, and planning and portfolio management; and third-party mutual funds, such as no-load mutual funds, proprietary mutual funds, and other third-party mutual funds, as well as mutual fund trading and clearing services to broker dealers. Further, the company offers third-party and proprietary exchange-traded funds; research, analytic tools, performance reports, market analysis, and educational materials; custodial, trading, technology, practice management, trust asset, and other support services to independent investment advisors; and retirement plan recordkeeping and related services, retirement plan trust and custody services, specialty brokerage services, and mutual fund clearing services. It operates primarily in the United States, the United Kingdom, and Hong Kong. The company was founded in 1971 and is headquartered in San Francisco, California.
Advisors' Opinion:- [By Dan Burrows]
First-quarter earnings season is supposed to be a dud, but don’t tell that to Coca-Cola (KO), Johnson & Johnson (JNJ) or Charles Schwab (SCHW). These three blue chips delivered some market-pleasing results Tuesday, helping KO stock, JNJ stock and SCHW stock to take off.
10 Best Quality Stocks To Own For 2014: Uroplasty Inc (UPI)
Uroplasty, Inc., incorporated in January 1992, is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company�� primary focus is on two products: the Urgent PC Neuromodulation system and Macroplastique Implants. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique Implants a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company�� Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux.
Urgent PC Neuromodulation System
Using a small-gauge needle electrode inserted above the ankle, the Urgent PC System delivers electrical impulses to the tibial nerve that travel to the sacral nerve plexus, a control center for pelvic floor and bladder function. Components of the Urgent PC system include a hair-width needle electrode, a lead set, and an external, handheld, battery-powered stimulator. For each 30-minute, office-based therapy session, the physician or other qualified healthcare provider inserts the needle electrode in the patient�� lower leg and connects the electrode to the stimulator. Typically, a patient undergoes 12 consecutive weekly treatment sessions, with follow-up maintenance treatments as required to sustain the therapeutic effect. The Company has received regulatory clearances for sale of the Urgent PC system in the United States, Canada and Europe. It also has launched its second generation Urgent PC system.
Macroplastique
Macroplastique is designed to restore the patient�� urinary contine! nce immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. Macroplastique does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site. The Company has sold Macroplastique for several urological indications in over 40 countries outside the United States.
Other Uroplasty Products
The Company markets outside of the United States minimally invasive products to address fecal incontinence. Its PTQ Implants offer minimally invasive, soft-textured permanent implant for treatment of fecal incontinence. The PTQ Implants are implanted circumferentially into the submucosa of the anal canal, creating a bulking and supportive effect similar to that of Macroplastique injection for the treatment of stress urinary incontinence. The PTQ is Conformite Europeenne (CE) marked and is sold outside the United States in various international markets. The Urgent PC is also CE marked and sold outside of the United States for the treatment of fecal incontinence. In addition to urological applications, the Company markets its tissue bulking material outside the United States for otolaryngology vocal cord rehabilitation applications under the trade name VOX Implants. In the Netherlands and the United Kingdom only, the Company distributes certain wound care products in accordance with a distributor agreement.
The Company competes with Pfizer Inc., Johnson and Johnson, Novartis, Allergan, GlaxoSmithKline, Carbon Medical Technologies, BioForm, Inc., Q-Med AB and Contura.
Advisors' Opinion:- [By Lisa Levin]
Uroplasty (NASDAQ: UPI) shares reached a new 52-week high of $5.22 after the company reported strong Q3 results.
Juniper Networks (NYSE: JNPR) shares gained 8.23% to touch a new 52-week high of $28.15 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00.
No comments:
Post a Comment